Clariant

Pandemic sustaining the portfolio

31/07/20 -"Clariant did quite well in the pandemic as speciality chemicals have offerings to help manage the crisis better. This does not necessarily mean they are “bullet proof” chemicals but their ..."

PDF page sample
Pages
55
Language
English
Published on
31/07/20
Download
You may also be interested by these reports :
17/07/26
Q2 2026 underperformed due to lower deliveries and nitrate margins (Asia). Volumes seem deferred rather than lost. While European buying has picked ...
15/07/26
BASF reported mixed preliminary Q2 2026 results. Sales and EBITDA exceeded consensus, supported by stronger pricing and volumes, while reported net ...
13/07/26
Akzo Nobel has rejected another acquisition bid from Nippon. The cited reason for undervaluation is hardly surprising, given that the implied ...
10/07/26
Europe approves genome editing for crop improvement. This means a historical milestone and KWS should structurally benefit mid-term. Add, TP EUR 78 ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO